Stock Events

Navamedic 

kr30.7
6
+kr0+0% Monday 15:50

Statistics

Day High
30.7
Day Low
30.7
52W High
41.3
52W Low
30.7
Volume
65,224
Avg. Volume
134
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

31OctExpected
Q1 2024
Q2 2024
Next
-0.09
0.29
0.67
1.05
Expected EPS
0.3095584101
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0FDB.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk is a global healthcare company and a leading competitor in the pharmaceuticals sector, directly competing with Navamedic ASA in areas such as diabetes care and biopharmaceuticals.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a global biopharmaceutical company that competes with Navamedic ASA in the development and marketing of medications and healthcare products.
Merck
MRK
Mkt Cap300.25B
Merck & Co., Inc. is a global healthcare company that competes with Navamedic ASA in the pharmaceuticals sector, offering similar products in various therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson is a comprehensive healthcare company that competes across multiple segments, including pharmaceuticals, medical devices, and consumer health products, overlapping with Navamedic's market.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie is a research-based biopharmaceutical company that competes with Navamedic ASA in developing and marketing advanced therapies.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline is a global healthcare company that competes with Navamedic ASA in the pharmaceutical and healthcare product sectors, including prescription medicines and vaccines.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Navamedic ASA in developing and commercializing prescription medicines in various therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Navamedic ASA in the discovery, development, and delivery of medicines.
Sanofi
SNY
Mkt Cap141.43B
Sanofi is a global healthcare leader that competes with Navamedic ASA in the pharmaceuticals sector, offering a wide range of medicines and vaccines.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines, competing with Navamedic ASA in the generics market and in the development of new treatments.

About

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.
Show more...
CEO
Ms. Kathrine E. Gamborg Andreassen
Employees
45
Country
NO
ISIN
NO0010205966

Listings